Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-Negative Inflammatory Breast Cancer (IBC)
Sponsor: Boehringer Ingelheim
Terminated
Slow Accrual
Other terminated trials from Boehringer Ingelheim
Other Breast Cancer trials with similar outcome
This PHASE2 trial investigates Breast Cancer and is currently terminated or withdrawn. Boehringer Ingelheim leads this study, which shows 10 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Aug 2018 — Aug 2019 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 5 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .